The patents cover psychedelic-based therapeutics, including monotherapy. “We have great confidence in our collaboration with Clearmind," SpiSparc CEO Oz Adler says. Get access to the leaderboards ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback